Introduction
As the most common cancer among women in modern societies, breast cancer is a complex and important disease. The average patient who dies with the disease loses about two decades of life, so that nearly 2 million women-years of life are lost annually to breast cancer in the United States and Europe (1) . Although about 87% of all cases survive for 5 years, nearly half of all women die from to breast cancer by one decade after diagnosis (1) (2) (3) .
About one-third of all cases of breast cancer can be attributed to recognized risk factors. Neither changes in established risk factors nor screening practices completely account for the persisting 1% annual increase in the incidence of breast cancer. Similarly, changes in risk factors or in screening practices do not explain geographic variations in prevalence of the disease (1) (2) (3) (4) . Inherited germ cell mutations occur in about 5% of all cases and in about 30% of cases under 40 years of age (3) (4) (5) (6) .
The common tie linking most of the established risk factors, aside from these mutations, is greater cumulative exposure to bioavailable 17,-estradiol (E2) (4, (7) (8) (9) (10) (11) . Bioavailable E2 is defined as a free hormone not bound to steroid hormonebinding globulin (SHBG) or weakly bound to albumin (9) (10) (11) (12) . Women with elevated levels of bioavailable E2 have a 2-to 4-fold excess risk of breast cancer (10) . Bioavailable E2 can diffuse into cells and subsequently be taken into the nucleus where it can bind to the estrogen receptor (ER). The hormone also can be converted in the cytoplasm into other biologically active metabolites and free radicals (4, 7) . In addition, other hormones, such as androgens and progestagens, can influence the production and metabolism of E2 (4, (9) (10) (11) (12) . The hormone-SHBG complex bound to the cell surface receptor induces cAMP-mediated phosphorylation (12) .
Medical Hypothesis
We have previously suggested that compounds functioning as xenoestrogens affect the rate and type of estradiol metabolites formed. Xenoestrogens may also bind directly with the ER to modulate breast cell proliferation and thereby influence the development of breast cancer and other hormonally mediated diseases (9, 11, 12) . In this report we expand the hypothesis to include a more detailed consideration of possible genetic-hormonal-environmental interactions (3, 4) , including the complex relationship among estrogens, androgens, their antagonists, and other hormones in breast cancer development.
Based on recent experimental and epidemiologic findings in this laboratory and elsewhere (4, 9, 11, 13) , we hypothesize that prenatal, adolescent, or midlife exposure to endogenous endocrine agents, xenohormones, or their metabolites can have bifunctional effects on the risk of developing breast cancer.
We also hypothesize that some xenohormonal exposures can, through redox cycling between estrogens and their corresponding quinones, yield reactive oxygen species that can cause structural oxidative damage to DNA and increase rates of oxidative DNA base modifications (7, 8, (14) (15) (16) .
Lipid oxidation products may also function as endogenous DNA damaging-agents (17 (4, 11) . Endogenous E2 and most natural plant estrogens (phytoestrogens) are metabolized and excreted relatively rapidly and readily bind to SHBG, whereas most xenoestrogens do not appear to have this binding capacity (11, 12, (23) (24) (25) . Moreover, the half-life of some lipophilic xenoestrogens, such as the organochlorine pesticides, can extend over several decades, in contrast to most natural estrogens, which are metabolized completely within several minutes or hours.
We and others (9-13,23-24) have suggested that two competing, mutually exclusive enzymatic pathways can alter the production of bioavailable estradiol. Pathway 1 inserts a hydroxyl (-OH) function at the C2-position and yields the catechol estrogen 2-hydroxyestrone (2-OHE1), a weakly estrogenic metabolite. Pathway 2 adds an OH at the C16a position and yields 16a-hydroxyestrone (16a-OHE1); this creates a fully potent estrogenic metabolite that can covalently bind to the ER (Figure 4 (25) . In contrast, 2-OHE1 lacks these activities and downregulates the effects of DMBA (28) (29) . In carcinogen initiated and in tumor-derived cells, 16a-OHE1 enhances, while 2-OHE1 inhibits, the expression of transformed phenotype (11, 13, 24, 26) . Similar changes have been reported in the human mammary explant and cell culture models (13, 28 (11, 24, 31) .
The ratio of 16a-hydroxyestrone to 2-hydroxyestrone has been found to be elevated in women and experimental animals with high rates of mammary tumors (13, 30, 32) . In human mammary carcinoma cell cultures, some organochlorine pesticides activate the type of Cyp450 that is responsible for 16a-hydroxyestrone formation and produce elevated metabolite ratios, comparable to that induced by the known rodent carcinogen DMBA (24 (7, 8, (36) (37) (38) . Microsomes from human fibroadenoma and adenocarcinoma exhibit higher levels of 4-OHE2 than of 2-OHE2 compared to normal breast tissue (7, 8) . In vivo and in vitro studies from our laboratory have shown that during mammary carcinogenesis, formation of 2-OHE1 is decreased while that of 16a-OHE1 is increased, and agents that increase 2-OHE1 inhibit carcinogenesis (26, 28, 29, 39) . Thus positive regulation of growth by 16a-OHE1, 4-OHE1, and 4-OHE2 and negative regulation by 2-OHE1 and 2-OHE2 may be consistent with the estrogenic or antiestrogenic properties of specific metabolites of E2. Despite the pleiotropic effects of E2 metabolites, the general consensus is that bioavailable E2 has an important role in the risk for breast cancer (4, 9, 11, 23, 35) . The (5, 6, 26, 33) . In addition, growth factors and hormone receptors can also independently stimulate cell proliferation or activate hormone-responsive genes without causing structural damage to DNA (3, 4, 17, 26, 33 (7, 8, (14) (15) (16) (36) (37) (38) . Free-radical induced damage may also cause the loss of tumor suppressor gene function, reduce natural killer cells, impair enzymatic detoxification processes, or alter growth factor synthesis.
Several investigations demonstrate that hydroxyl (-OH) radicals and oxidative metabolites of aromatic hydrocarbons can irreparably and specifically modify the structure of DNA, leading to mutagenesis and carcinogenesis (7, 8, (14) (15) (16) 40) . Distinctive types of -OH-induced modifications in DNA bases have been detected in women with breast cancer and in those at risk for the disease, compared to controls, who have undergone reduction mammoplasty. DNA from mammoplasty patients had relatively higher proportions of ring opening product of adenine, 4,6-diamino-5-formamidopyrimidine (Fapy-A), whereas cancer patients had markedly lower levels of Fapy-A and higher levels of 8-hydroxyquanine (16) . It has been suggested that the relevance of oxidative DNA damage in breast cancer reduction is predominantly due to H202 generation. H202 can cross the nuclear membrane, where it is converted by the iron-or coppercatalyzed Fenton reaction to the free radical *OH. Some xenoestrogens and estrogen metabolites may promote the production of free radicals by redox cycling of H202 mediated by cytochrome P450 oxidase and reductase, leading to production of DNA-damaging reactive oxygen species.
Another critical pathway to breast cancer can arise from agents that affect genes for regulatory proteins, such as phosphatidylinositol-3-kinases (PI-3-kinases). These 10 years and then resumes an increasing, but more modest, slope. The ages of this plateau correspond to the period of perimenopause, when the ovaries begin to produce less estrogen and progestin (44) . It is tempting to speculate that the renewed surge in breast cancer after menopause, especially in obese women, might be linked with xenoestrogens and with the production of endogenous estrogens that would be greatest in those with proportionally more body fat. Also, obese women would have higher rates of membrane lipid damage (9) (10) (11) 23, 35, 42, 45) .
With respect to breast cancer, most of the confirmed risk factors, which relate to reproductive behavior and dietary factors, are not easily changed by social policy. Many of the proposed interventions to reduce breast cancer involve the lifelong use of pharmaceutical agents to change hormonal metabolism or the advocacy of radical changes in diet, lifestyle, or even reproductive behavior. As for the latter point, a generation of women that has struggled long for reproductive freedom is unlikely to accept constraints on their reproductive choices.
This hypothesis has major implications for breast cancer screening, prevention, treatment, and management. Biologic markers of structural and functional damage to DNA and of estradiol metabolism could prove useful for identifying persons at risk of developing breast cancer, assist in prognostic predictions, and provide baselines to assess the efficacy of potential therapeutic and nutritional interventions for prevention, treatment, and management of the disease.
